Embedded Files
Researchers from STH and the University of Strathclyde have led the largest clinical study to date investigating speech therapy for people with a rare, rapidly progressive and fatal neurological condition.
The randomised controlled trial compared two approaches to speech therapy for those with a cerebellar sub-type of Muscular System Atrophy (MSA-C), including a novel intervention model developed at the University of Strathclyde, known as ClearSpeechTogether.
The study demonstrated that both treatments improved participants’ communication confidence and participation, with ClearSpeechTogether showing early indications of greater benefit.
Degenerative condition
MSA-C is a degenerative condition that severely affects balance, movement, and speech. Speech problems often emerge early, affecting patients’ ability to communicate, which can lead to social withdrawal and diminished quality of life.
The Strathclyde model combines one-to-one therapy with peer-led online group sessions, offering intensive yet sustainable treatment through a telehealth model. Participants underwent 24 sessions over six weeks, achieving high attendance and adherence despite the progressive nature of their condition.
Social support
The research, published in The Cerebellum, and funded by the MSA Trust, also found that participants valued the social support and empowerment gained through the group format, which some continued independently beyond the trial.
“We were pleased to see that individuals with MSA-C, including those at more advanced stages, were able to take part fully in this therapy and reported meaningful improvements in their communication.
“Our results suggest that ClearSpeechTogether offers a promising, cost-effective model that could help people with MSA-C maintain their voice and social connections for longer.
“It provides strong evidence for the feasibility of conducting larger trials and highlights the need for accessible, high-quality speech therapy options for people living with rare neurodegenerative conditions.”
Reader in Speech and Language Therapy at the University of Strathclyde and lead author of the study, Professor Anja Lowit
“It is very rewarding to be able to offer something practical and beneficial to this group of patients who unfortunately follow a very progressive course and are severely disabled. There is currently no effective treatment for this condition.”
Consultant Neurologist and Head of the Sheffield Ataxia Centre Professor Marios Hadjivassiliou
The NIHR funds, enables and delivers world-leading health and social care research that improves people's health and wellbeing and promotes economic growth.
NIHR Biomedical Research Centres (BRCs) are collaborations between NHS organisations and universities. They bring together academics and clinicians to translate scientific discoveries into potential new treatments, diagnostics and technologies.
Page updated
Report abuse